News

Date Title View
Toggle Summary Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
- Submitted as a 505(b)(2) with an Expected Ten-Month FDA Review - DURHAM, N.C. --(BUSINESS WIRE)--May 15, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment
View HTML
Toggle Summary Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
Conference Call and Webcast Today, May 8 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--May 8, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial Counsel
DURHAM, N.C. --(BUSINESS WIRE)--May 1, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye,
View HTML
Toggle Summary Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution) 0.02%
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 30, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 26, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its first quarter 2018 financial results will be released after the market closes on Tuesday, May 8, 2018 . Following the release, the Company will host a live
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan™
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 12, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 21, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Oppenheimer & Co. 28th Annual Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 14, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 7, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance
Conference Call and Webcast Today, February 28 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Feb. 28, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML